Solara Active Pharma Sciences Share Price Today (SOLARA)
TODAY IN ONE LINE
SOLARA edged up 0.4% on light volume, in line with Nifty's -0.0% move, supported by recent strong earnings.
With a market cap of ₹2,445.11 Cr., it trades at a P/E of -1492.06. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Solara Active Pharma Sciences flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 41.9% and Profit up 516.0%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.01x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest Solara Active Pharma Sciences News
What changed recently?
Recent events, corporate actions, and announcements.
Solara Active Pharma Sciences Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Solara Active Pharma Sciences Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Solara Active Pharma Sciences Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Solara Active Pharma Sciences Limited — derived from the live tape, not yesterday's close.
Solara Active Pharma Sciences Limited last traded at ₹507 with an intraday range of ₹495.2–₹509 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹507.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 539.87 | +32.87 | +6.48% |
| R3 | 526.07 | +19.07 | +3.76% |
| R2 | 517.53 | +10.53 | +2.08% |
| R1 | 512.27 | +5.27 | +1.04% |
| PIVOT | 503.73 | -3.27 | -0.64% |
| CURRENT | 507.00 | — | — |
| S1 | 498.47 | -8.53 | -1.68% |
| S2 | 489.93 | -17.07 | -3.37% |
| S3 | 484.67 | -22.33 | -4.40% |
| S4 | 470.87 | -36.13 | -7.13% |
SOLARA is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹495.55–₹506.7
Trading Inside opening range
Solara Active Pharma Sciences Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Solara Active Pharma Sciences Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Solara Active Pharma Sciences Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,445.11 Cr. and reported EPS of ₹-1.68.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,284 | 1,369 ▲ 6.6% |
| Sales Growth YoY %Derived | -0.40% | 6.64% |
| Other Income | 8 | 6 ▼ 26.0% |
| Total Income | 1,292 | 1,375 ▲ 6.4% |
| 626 | 685 ▲ 9.3% | |
| Gross ProfitDerived | 657 | 684 ▲ 4.1% |
| Gross Margin %Derived | 51.21% | 50.00% |
| 451 | 498 ▲ 10.3% | |
| EBITDA (Operating Profit)Derived | 206 | 187 ▼ 9.5% |
| OPM %Derived | 16.07% | 13.64% |
| 214 | 189 ▼ 11.9% | |
| Profit Before Tax (PBT) | 1 | -7 ▼ 1472.2% |
| — | — | |
| Effective Tax %Derived | — | — |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 1 | -7 ▼ 1472.2% |
| Less: Non-controlling Interests | -0 | — ▲ 100.0% |
| Net Profit (Owner's PAT)Derived | 1 | -7 ▼ 1469.7% |
| Net Profit Margin %Derived | 0.04% | -0.54% |
| PAT Growth YoY %Derived | 100.10% | -1,469.69% |
| Earnings Per Share (EPS ₹) | 0.11 | -1.54 ▼ 1500.0% |
| Diluted Shares Outstanding (Cr) | 5 | 5 ▲ 0.3% |
| Other Comprehensive Income (Net of Tax) | 1 | 3 ▲ 190.8% |
| Total Expenses (incl. D&A & Interest) | 1,292 | 1,383 ▲ 7.0% |
| Material Cost % of RevenueDerived | 45.31% | 49.14% |
| Employee Cost % of RevenueDerived | 16.49% | 16.01% |
| Other Cost % of RevenueDerived | 18.65% | 20.35% |
| Interest Coverage (x)Derived | 0.93x | 0.92x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,387 | 1,322 ▼ 4.7% | 1,617 ▲ 22.3% | 1,268 ▼ 21.6% | 1,444 ▲ 13.8% | 1,289 ▼ 10.7% | 1,284 ▼ 0.4% | 1,369 ▲ 6.6% | |
| Sales Growth YoY %Derived | — | -4.68% | 22.33% | -21.56% | 13.83% | -10.73% | -0.40% | 6.64% | |
| Other Income | 12 | 28 ▲ 122.3% | 29 ▲ 4.5% | 20 ▼ 30.4% | 23 ▲ 12.6% | 5 ▼ 76.2% | 8 ▲ 54.9% | 6 ▼ 26.0% | |
| Total Income | 1,399 | 1,349 ▼ 3.6% | 1,646 ▲ 22.0% | 1,288 ▼ 21.7% | 1,466 ▲ 13.8% | 1,294 ▼ 11.7% | 1,292 ▼ 0.2% | 1,375 ▲ 6.4% | |
705 | 599 ▼ 15.0% | 724 ▲ 21.0% | 654 ▼ 9.7% | 789 ▲ 20.6% | 805 ▲ 2.1% | 626 ▼ 22.2% | 685 ▲ 9.3% | ||
| Gross ProfitDerived | 682 | 723 ▲ 6.0% | 892 ▲ 23.5% | 614 ▼ 31.2% | 655 ▲ 6.6% | 484 ▼ 26.1% | 657 ▲ 35.8% | 684 ▲ 4.1% | |
| Gross Margin %Derived | 49.17% | 54.69% | 55.20% | 48.45% | 45.37% | 37.54% | 51.21% | 50.00% | |
461 | 463 ▲ 0.5% | 507 ▲ 9.3% | 534 ▲ 5.5% | 521 ▼ 2.5% | 579 ▲ 11.1% | 451 ▼ 22.1% | 498 ▲ 10.3% | ||
| EBITDA (Operating Profit)Derived | 221 | 259 ▲ 17.5% | 386 ▲ 48.7% | 80 ▼ 79.3% | 134 ▲ 67.4% | -95 ▼ 171.1% | 206 ▲ 316.7% | 187 ▼ 9.5% | |
| OPM %Derived | 15.92% | 19.63% | 23.87% | 6.31% | 9.27% | -7.38% | 16.07% | 13.64% | |
166 | 172 ▲ 4.0% | 193 ▲ 12.3% | 184 ▼ 4.7% | 201 ▲ 9.3% | 18 ▼ 90.9% | 214 ▲ 1071.6% | 189 ▼ 11.9% | ||
| Profit Before Tax (PBT) | 68 | 115 ▲ 69.8% | 222 ▲ 92.8% | -91 ▼ 141.1% | -45 ▲ 50.8% | -488 ▼ 990.0% | 1 ▲ 100.1% | -7 ▼ 1472.2% | |
1 | 0 ▼ 32.8% | 0 ▼ 61.5% | -33 ▼ 21973.3% | -23 ▲ 31.2% | 79 ▲ 448.0% | — ▼ 100.0% | — | ||
| Effective Tax %Derived | 0.86% | 0.34% | 0.07% | 36.02% | 50.37% | -16.08% | — | — | |
| Profit/Loss from Discontinued Ops | -8 | — ▲ 100.0% | — | — | — | — | — | — | |
| Total Profit for Period | 59 | 115 ▲ 92.7% | 221 ▲ 93.3% | -58 ▼ 126.3% | -22 ▲ 61.8% | -567 ▼ 2449.3% | 1 ▲ 100.1% | -7 ▼ 1472.2% | |
| Less: Non-controlling Interests | -0 | -0 ▲ 10.0% | -0 ▲ 44.4% | -0 ▼ 180.0% | -0 ▲ 50.0% | 0 ▲ 714.3% | -0 ▼ 100.2% | — ▲ 100.0% | |
| Net Profit (Owner's PAT)Derived | 60 | 115 ▲ 92.6% | 221 ▲ 93.2% | -58 ▼ 126.3% | -22 ▲ 61.9% | -567 ▼ 2459.3% | 1 ▲ 100.1% | -7 ▼ 1469.7% | |
| Net Profit Margin %Derived | 4.29% | 8.67% | 13.69% | -4.58% | -1.54% | -44.02% | 0.04% | -0.54% | |
| PAT Growth YoY %Derived | — | 92.56% | 93.18% | -126.26% | 61.87% | -2,459.27% | 100.10% | -1,469.69% | |
| Earnings Per Share (EPS ₹) | 17.29 | 32.01 ▲ 85.1% | 46.22 ▲ 44.4% | -12.12 ▼ 126.2% | -4.62 ▲ 61.9% | -118.22 ▼ 2458.9% | 0.11 ▲ 100.1% | -1.54 ▼ 1500.0% | |
| Diluted Shares Outstanding (Cr) | 3 | 4 ▲ 4.2% | 5 ▲ 33.8% | 5 ▲ 0.2% | 5 ▲ 0.0% | 5 ▲ 0.0% | 5 ▲ 0.1% | 5 ▲ 0.3% | |
| Other Comprehensive Income (Net of Tax) | -3 | -4 ▼ 30.6% | -2 ▲ 35.3% | 2 ▲ 178.8% | -2 ▼ 209.0% | 0 ▲ 123.8% | 1 ▲ 100.0% | 3 ▲ 190.8% | |
| Total Expenses (incl. D&A & Interest) | 1,331 | 1,234 ▼ 7.3% | 1,424 ▲ 15.4% | 1,379 ▼ 3.1% | 1,511 ▲ 9.5% | 1,783 ▲ 18.0% | 1,292 ▼ 27.6% | 1,383 ▲ 7.0% | |
| Material Cost % of RevenueDerived | 52.61% | 45.56% | 42.29% | 67.72% | 53.60% | 59.01% | 45.31% | 49.14% | |
| Employee Cost % of RevenueDerived | 13.40% | 15.44% | 14.19% | 18.63% | 15.84% | 18.92% | 16.49% | 16.01% | |
| Other Cost % of RevenueDerived | 19.85% | 19.62% | 17.15% | 23.51% | 20.26% | 26.00% | 18.65% | 20.35% | |
| Interest Coverage (x)Derived | 1.67x | 2.12x | 3.28x | -0.43x | 0.25x | -1.89x | 0.93x | 0.92x |
Solara Active Pharma Sciences segment analysis : revenue and profit mix.
Disclosed business segments at Solara Active Pharma Sciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Solara Active Pharma Sciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Solara Active Pharma Sciences Limited.
Our AI distills the core fundamental drivers supporting Solara Active Pharma Sciences Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Solara Active Pharma Sciences Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Promoter holdings stable at 42%, demonstrating management confidence and alignment
Latest quarterly PAT surged to ₹10.52 Cr, signaling earnings recovery momentum
TTM revenue growth 41.9% demonstrates strong top-line momentum despite quarterly softness
Debt-to-equity ratio 0.0055 suggests very manageable financial leverage structure
Operating margin 6.36% TTM reflects moderate core operational efficiency gains
Key Risks.
Net margin -0.54% TTM and negative annual earnings undermine profitability sustainability
ROE -0.13% indicates poor capital returns for equity investors currently
Latest quarterly sales ₹319 Cr declined 12.2% YoY, reflecting weakening demand
Negative EPS -1.68 annually signals persistent earnings challenges ahead
Current ratio 0.91 indicates liquidity stress below healthy 1.0 threshold
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.05. Balance sheet risk re-prices growth multiples fast.
Solara Active Pharma Sciences Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Solara Active Pharma Sciences Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Solara Active Pharma Sciences Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Solara Active Pharma Sciences Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Solara Active Pharma Sciences Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Solara Active Pharma Sciences Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Solara Active Pharma Sciences Limited stood at 59.6% of traded volume, against a 20-day average of 47.4%.
Solara Active Pharma Sciences announcements: results, concalls, ratings, M&A.
Filings Solara Active Pharma Sciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Solara Active Pharma Sciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 143 documents below.
Copy of Newspaper Publication
Solara Active Pharma Sciences Limited has informed the Exchange about Copy of Newspaper Publication providing extract of the unaudited financial…
Updates
Solara Active Pharma Sciences Limited has informed the Exchange regarding Submission of Machine Readable copy of financial results for the quarter…
Analysts/Institutional Investor Meet/Con. Call Updates
Solara Active Pharma Sciences Limited has intimated the Exchange about the Audio Recording of the Q1 FY27 Earnings Call held on July 23, 2026 at…
Monitoring Agency Report
Monitoring Agency Report for the quarter ended June 30, 2026
Statement of deviation(s) or variation(s) under Reg. 32
Solara Active Pharma Sciences Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
Investor decks & rating reports.
Solara Active Pharma Sciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Solara Active Pharma Sciences has declared, sequenced by announce and record date.
Solara Active Pharma Sciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Solara Active Pharma Sciences insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Solara Active Pharma Sciences as reported to SEBI — buying and selling signals from the people who know the business best.
Solara Active Pharma Sciences insider activity below tracks 7 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Sandeep Shashikantha Rao | Insider | 04 Jun 2025 | buy | +1.0 K | ₹4.74 L | ₹473.99 |
| Kausalya Santhanam | Insider | 11 Mar 2025 | buy | +1.0 K | ₹5 L | ₹500.06 |
| Pronomz Ventures LLP | Insider | 28 Feb 2025 | buy | +13.6 K | ₹62.76 L | ₹461.50 |
| Pronomz Ventures LLP | Insider | 24 Feb 2025 | buy | +1.52 L | ₹7.2 Cr. | ₹473.48 |
| Pronomz Ventures LLP | Insider | 24 Feb 2025 | buy | +2.16 L | ₹10.26 Cr. | ₹474.31 |
| Pronomz Ventures LLP | Insider | 11 Feb 2025 | buy | +34.0 K | ₹1.78 Cr. | ₹524.82 |
| Pronomz Ventures LLP | Insider | 03 Feb 2025 | buy | +78.0 K | ₹4.03 Cr. | ₹516.68 |
About Solara Active Pharma Sciences Limited: business, sector, key facts.
What Solara Active Pharma Sciences Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Solara Active Pharma Sciences Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SOLARA, BSE: 541540.
Solara Active Pharma Sciences Limited is a global pharmaceutical company specializing in the manufacture, production, formulation, and distribution of active pharmaceutical ingredients (APIs). Their operations span a wide geographical area, including India, the Asia-Pacific region, Europe, North America, and South America, facilitating international trade and sales.
The company's API portfolio is extensive and covers a broad range of therapeutic areas. They produce APIs for various conditions, including amyotrophic lateral sclerosis, cardiovascular diseases, neurological disorders (like Parkinson's disease), infections (antibiotics, antifungals), and respiratory ailments (like asthma). Other therapeutic categories include anti-inflammatory, anti-cancer, anti-hypertensive, and anti-psychotic medications, amongst many others. The sheer breadth of their API offerings highlights their diverse capabilities and expertise within the pharmaceutical manufacturing sector.
Beyond API production, Solara Active Pharma Sciences also provides comprehensive contract research and manufacturing services (CRAMS). This service offering includes contract development and manufacturing of APIs, along with crucial support services such as analytical testing, impurity synthesis, and regulatory assistance. These added services enhance their value proposition to pharmaceutical clients seeking outsourced manufacturing and development solutions.
In essence, Solara Active Pharma Sciences Limited functions as a fully integrated pharmaceutical company. They not only manufacture and distribute a vast array of APIs for various therapeutic applications but also offer comprehensive CRAMS capabilities, enabling them to serve a diverse client base across the global pharmaceutical industry. Their international reach and broad portfolio position them as a significant player in the API market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Solara Active Pharma Sciences Limited (SOLARA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Solara Active Pharma Sciences Limited (SOLARA)?
The current share price of Solara Active Pharma Sciences Limited (SOLARA) is ₹507. Today, the stock has gained by ₹2.00 (0.40%), trading in a range of ₹495.2 to ₹509. The stock opened at ₹504.35 with a trading volume of 1,93,855 shares.
02Is Solara Active Pharma Sciences Limited stock a good investment for long-term?
Solara Active Pharma Sciences Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,445.11 crores, P/E ratio of -1492.06, ROE of -0.13%, and ROCE of 4.86%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Solara Active Pharma Sciences Limited stock?
The 52-week high price of Solara Active Pharma Sciences Limited (SOLARA) is ₹712, while the 52-week low is ₹422. Currently trading at ₹507, the stock is 29.3% away from its 52-week low and 28.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Solara Active Pharma Sciences Limited stock at the current price?
Whether to buy Solara Active Pharma Sciences Limited stock at ₹507 depends on multiple factors. The stock is currently trading with a P/E ratio of -1492.06 and P/B ratio of 1.95. Today's performance shows a gain of 0.40%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Solara Active Pharma Sciences Limited and when is the next dividend?
Solara Active Pharma Sciences Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹507, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Solara Active Pharma Sciences Limited?
Solara Active Pharma Sciences Limited's key financial metrics include: P/E Ratio: -1492.06, P/B Ratio: 1.95, ROE: -0.13%, ROCE: 4.86%, Dividend Yield: 0.00%, EPS: ₹-1.68, Book Value: ₹287.12, and Debt-to-Equity: 0.55. The company's market cap stands at ₹2,445.11 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Solara Active Pharma Sciences Limited stock performing today in the market?
Solara Active Pharma Sciences Limited stock opened at ₹504.35 and is currently trading at ₹507, showing a gain of ₹2.00 (0.40%). The intraday high is ₹509 and low is ₹495.2. The trading volume stands at 1,93,855 shares, indicating moderate market participation today.
08What is the P/E ratio of Solara Active Pharma Sciences Limited and what does it indicate?
Solara Active Pharma Sciences Limited has a Price-to-Earnings (P/E) ratio of -1492.06, which means investors are willing to pay ₹-1492.06 for every ₹1 of earnings. With an EPS of ₹-1.68, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Solara Active Pharma Sciences Limited (SOLARA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.